I led an analysis of AI-enabled therapies that have entered interventional clinical trials -- while most assets (over 120 of them!) are still early (ph 1/2), there are numerous exampled of repurposed drugs and also many with novel targets.
AI-driven drug rescue could become a major biotech advantage by finding new uses and patient targets for previously abandoned compounds, reducing both cost and development time.
I led an analysis of AI-enabled therapies that have entered interventional clinical trials -- while most assets (over 120 of them!) are still early (ph 1/2), there are numerous exampled of repurposed drugs and also many with novel targets.
https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11072
Thanks, it seems i credibly useful. I am going to cite your work in the upcoming 2026 AI pharma industry landscape report.
AI-driven drug rescue could become a major biotech advantage by finding new uses and patient targets for previously abandoned compounds, reducing both cost and development time.
Thats right